Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven oncology drug discovery, has announced significant advancements in applying its RADR® AI platform to the development of antibody-drug conjugates (ADCs). As the global ADC market is projected to exceed $30.4 billion by 2028, the increasing interest in ADCs has led to major acquisitions valued at over $10 billion by leading biotech firms. Lantern Pharma is positioning itself at the forefront of this sector, actively developing multiple ADC candidates, including a collaboration with MAGICBULLET::Reloaded Initiative at the University of Bielefeld in Germany.
In a peer-reviewed study published in PLOS ONE, Lantern Pharma researchers demonstrated the power of their AI-driven ADC module, which identified 82 potential ADC targets and 290 target-indication combinations while screening over 50,000 compounds. Among these, 22 targets have already been clinically validated, while 60 novel targets present new opportunities for intellectual property, portfolio expansion, and strategic licensing. The AI module further characterized highly potent payload molecules, optimizing their effectiveness through the RADR® platform’s molecular database and advanced machine learning models.
Panna Sharma, CEO & President of Lantern Pharma, emphasized that this AI-powered breakthrough is transforming the traditionally costly and time-intensive ADC development process. He noted that the integration of mutation profiles with target expression data enables precise therapeutic combinations, potentially reducing ADC development timelines by 30–50% and cutting costs by up to 60%.
The research utilizes Lantern’s proprietary RADR® AI platform, analyzing transcriptomics, proteomics, and mutation profiles across 22 tumor types to predict mutation-specific responses. This ability to optimize patient stratification in clinical trials could significantly improve success rates while reducing development costs. Kishor Bhatia, Ph.D., Chief Scientific Officer at Lantern Pharma, highlighted the platform’s potential for expanding ADC pipelines through strategic partnerships with pharmaceutical companies aiming to accelerate drug development.
The AI-powered ADC module continues to evolve as Lantern Pharma refines its data and computational capabilities, aiming to establish a cost-efficient, scalable framework for ADC development. The full research findings, published in PLOS ONE, further validate the potential of AI-driven oncology innovation. Lantern Pharma remains committed to leveraging machine learning and large-scale data analysis to advance its pipeline of targeted cancer therapies and provide life-changing treatment solutions to patients worldwide.
